GenAhead Bio licenses CRISPR/Cas9 from Broad Institute

GenAhead Bio Incorporated ("GenAhead") announced today the signing of a non-exclusive commercial research tool and services license agreement to CRISPR / Cas9 genome editing technology from the Broad Institute of MIT and Harvard.

GenAhead began operations in 2018 as a spin-out from Takeda Pharmaceutical Company Limited and has since leveraged the latest CRISPR / Cas9 technology and gene delivery expertise to provide a highly efficient and accurate platform for genome editing.
Dr. Tsukasa Sugo, CEO of GenAhead Bio said "The license from Broad Institute enables us to offer our CRISPR / Cas9 genome editing service with high knock-in (KI) efficiency."